NUVL

Nuvalent, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.00
52-Week Range: $71.13 – $123.99
Market Cap: $9.79B
P/E (TTM): —
EPS (TTM): -6.06
Dividend Yield: —

Advanced Metrics

Price/Book: 8.33
PEG Ratio: —
Return on Equity: -41.19%
Return on Assets: -22.51%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 16.14
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-180.43M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $8.51B

NUVL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$63.73M	$113.24M	$217.77M	$306.97M
Selling, General & Admin	$22.38M	$36.25M	$62.59M	$107.34M
Operating Expenses	$86.11M	$149.49M	$280.37M	$414.31M
Operating Income	-$86.11M	-$149.49M	-$280.37M	-$414.31M
EBITDA	-$86.11M	-$149.49M	-$280.37M	-$414.31M
Pretax Income	-$81.85M	-$126.22M	-$259.99M	-$424.79M
Income Tax	$0.00	$0.00	$764.00K	$585.00K
Net Income	-$81.85M	-$126.22M	-$260.76M	-$425.38M
Diluted EPS	-1.65	-2.17	-3.93	-5.85
Diluted Shares	49.67M	58.22M	66.41M	72.69M

NUVL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$241.81M	$335.39M	$145.69M	$261.75M
Current Assets	$477.99M	$726.49M	$1.13B	$1.39B
Total Assets	$482.46M	$732.38M	$1.14B	$1.41B
Current Liabilities	$19.48M	$31.82M	$54.02M	$91.17M
Total Liabilities	$19.48M	$31.82M	$71.96M	$164.37M
Retained Earnings	-$160.08M	-$286.30M	-$547.05M	-$972.43M
Shareholders' Equity	$462.98M	$700.56M	$1.07B	$1.25B
Working Capital	$458.51M	$694.66M	$1.08B	$1.30B

NUVL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$64.97M	-$99.74M	-$185.06M	-$275.21M
Free Cash Flow	-$64.97M	-$99.74M	-$185.06M	-$275.21M
Stock-Based Compensation	$10.32M	$25.56M	$60.58M	$86.50M
Investing Cash Flow	-$10.66M	-$143.53M	-$573.51M	-$124.08M
Financing Cash Flow	$248.92M	$336.85M	$568.88M	$515.34M
Net Change in Cash	$173.28M	$93.58M	-$189.70M	$116.05M

NUVL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$74.42M	$80.91M	$83.84M	$67.80M	$83.61M
Selling, General & Admin	$20.39M	$23.66M	$28.85M	$34.43M	$35.80M
Operating Expenses	$94.81M	$104.57M	$112.70M	$102.23M	$119.41M
Operating Income	-$94.81M	-$104.57M	-$112.70M	-$102.23M	-$119.41M
EBITDA	-$94.81M	-$104.57M	-$112.70M	-$102.23M	-$119.41M
Pretax Income	-$84.42M	-$99.51M	-$122.31M	-$118.55M	-$109.11M
Income Tax	$157.00K	$145.00K	$132.00K	$151.00K	$168.00K
Net Income	-$84.58M	-$99.65M	-$122.44M	-$118.70M	-$109.28M
Diluted EPS	-1.18	-1.39	-1.70	-1.58	-1.39
Diluted Shares	71.61M	71.84M	72.14M	75.12M	78.67M

NUVL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$120.83M	$127.47M	$115.75M	$261.75M	$159.73M
Current Assets	$1.09B	$1.02B	$956.95M	$1.39B	$1.31B
Total Assets	$1.11B	$1.04B	$979.91M	$1.41B	$1.33B
Current Liabilities	$75.03M	$75.15M	$89.15M	$91.17M	$81.05M
Total Liabilities	$94.75M	$100.80M	$134.51M	$164.37M	$156.78M
Retained Earnings	-$631.63M	-$731.29M	-$853.72M	-$972.43M	-$1.08B
Shareholders' Equity	$1.01B	$939.74M	$845.40M	$1.25B	$1.17B
Working Capital	$1.01B	$944.46M	$867.79M	$1.30B	$1.23B

NUVL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$54.82M	-$76.60M	-$70.46M	-$73.33M	-$92.40M
Free Cash Flow	-$54.82M	-$76.60M	-$70.46M	-$73.33M	-$92.40M
Stock-Based Compensation	$20.38M	$22.07M	$22.31M	$21.73M	$28.88M
Investing Cash Flow	$25.42M	$77.48M	$53.97M	-$280.94M	-$19.41M
Financing Cash Flow	$4.55M	$5.75M	$4.77M	$500.26M	$9.80M
Net Change in Cash	-$24.86M	$6.63M	-$11.72M	$145.99M	-$102.01M

Market Snapshot

About

Nuvalent, Inc. is a precision oncology company developing targeted therapies for patients with ROS1-positive and ALK-positive non-small cell lung cancer and other cancers driven by these kinase targets.